Finally, the elevated level of sPD-L1 after RT suggests that the combination of RT with immune checkpoint inhibitors may be a promising therapeutic strategy in gliomas, especially for patients with IDH-1 MUT gliomas. This evidence concerns the gene SPDL1 and central nervous system cancer.